(E)-2-methyl-6-octenoic acid | 133147-88-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (E)-2-methyl-6-octenoic acid
• 英文别名: (E)-2-methyloct-6-enoic acid
• CAS: 133147-88-3
• 化学式: C₉H₁₆O₂
• 分子量: 156.225
• InChiKey: FKBBGBFWNLFJEZ-ONEGZZNKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-2-methyl-6-octenoic acid 在 草酰氯 作用下， 以 苯 为溶剂， 生成
  参考文献：
  名称：

  二烷基烯酮与烯烃的分子内[2 + 2]环加成。烯酮与烯烃的分子内[2 + 2]环加成反应的区域化学

  摘要：

  不饱和二烷基烯酮7a，7b和7c经历分子内[2 + 2]环加成，得到8a（45％），9b（23％）和9c（45％）。即使二烷基烯酮的反应性不如单烷基烯酮，二烷基烯酮的分子内环加成比单烷基烯酮的分子内环加成具有更高的产率。乙烯酮17的分子内竞争实验确定，在分子内环加成中，反式烯烃的反应性比顺式烯烃高约33倍。酮36提供预期的双环[3.2.0]庚酮37中的22％和28％的双环[3.1.1]庚酮38。

  DOI：

  10.1016/s0040-4020(01)81460-5
• 作为产物：
  描述：

  反式-4-己烯基碘 、 丙酸 在 正丁基锂 、 二异丙胺 作用下， 生成 (E)-2-methyl-6-octenoic acid
  参考文献：
  名称：

  二烷基烯酮与烯烃的分子内[2 + 2]环加成。烯酮与烯烃的分子内[2 + 2]环加成反应的区域化学

  摘要：

  不饱和二烷基烯酮7a，7b和7c经历分子内[2 + 2]环加成，得到8a（45％），9b（23％）和9c（45％）。即使二烷基烯酮的反应性不如单烷基烯酮，二烷基烯酮的分子内环加成比单烷基烯酮的分子内环加成具有更高的产率。乙烯酮17的分子内竞争实验确定，在分子内环加成中，反式烯烃的反应性比顺式烯烃高约33倍。酮36提供预期的双环[3.2.0]庚酮37中的22％和28％的双环[3.1.1]庚酮38。

  DOI：

  10.1016/s0040-4020(01)81460-5

文献信息

• SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF
  申请人：Advinus Therapeutics Limited

  公开号：EP2903985A1

  公开（公告）日：2015-08-12
• COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE
  申请人：Flagship Pioneering Innovations V, Inc.

  公开号：US20210289794A1

  公开（公告）日：2021-09-23

  The invention comprises methods for decreasing colonization by a bacterium of a gut of a stink bug, the method comprising providing a composition comprising vanillin or an analog thereof; and delivering said composition to an egg from which the stink bug will hatch, whereby colonization by the bacterium within the gut of the stink bug hatched from the egg treated with the composition is decreased relative to a stink bug hatched from an untreated egg. In some embodiments, the decrease in colonization by the bacterium decreases the fitness of the stink bug, e.g., decreases reproductive ability, survival, rate of development, number of eggs, number of hatched eggs, adult emergence rate, body length, body width, body mass, or cuticle thickness. In some embodiments of the methods herein, the bacterial colonization-disrupting agent is an inhibitor of bacterial metabolism. In some embodiments, the bacterial colonization-disrupting agent is a polyhydroxyalkanoate (PHA) synthesis inhibitor.
• US5674905A
  申请人：——

  公开号：US5674905A

  公开（公告）日：1997-10-07
• [EN] TROPANE DERIVATIVE, CHELATION PRODUCT COMPRISING THIS TROPANE DERIVATIVE AND A METAL OR A METAL COMPLEX, AND RADIOPHARMACEUTICAL<br/>[FR] DERIVE DU TROPANE, PRODUIT DE CHELATION RENFERMANT CE DERIVE DU TROPANE ET METAL OU COMPLEXE METALLIQUE, ET RADIOPHARMACEUTIQUE
  申请人：SCHERING AG

  公开号：WO2003055879A2

  公开（公告）日：2003-07-10

  The present invention relates to a tropane derivative, to a chelation product composed of this tropane derivative and of a metal or of a metal complex, and to a radiopharmaceutical comprising the said product. The tropane derivative of the present invention is of following formula (I), in which X represents a compound for chelation of a metal or of a metal complex, the 6 and 7 carbons being bonded to one another or not being bonded to one another, in which: R1 is an alkyl or alkenyl, R2 is of the form -COOZ with Z chosen from H or an alkyl group, R3 represents a phenyl group; a phenylalkyl or phenylalkenyl group; a benzoate group or an oxo group, and in which the bond between the 2 and 3 carbons is a single or double bond.
• [EN] SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF<br/>[FR] COMPOSÉS SPIROCYCLIQUES ET LEURS COMPOSITIONS ET APPLICATIONS MÉDICINALES
  申请人：ADVINUS THERAPEUTICS LTD

  公开号：WO2014054053A1

  公开（公告）日：2014-04-10

  The present disclosure relates to a series of spirocyclic compounds of formula (I), their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates, hydrates, N-Oxides, Co crystals and formulations thereof. The disclosure also relates to process of preparation of these spirocyclic compounds. Formula (I). These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of acyl CoA diacyl glycerol acyltransferase 1 (DGAT1).